Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Anika Therapeutics (ANIK) over the last 15 years, with Q3 2025 value amounting to 0.07%.

  • Anika Therapeutics' Return on Capital Employed fell 1600.0% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year decrease of 1600.0%. This contributed to the annual value of 0.02% for FY2024, which is 300.0% down from last year.
  • Per Anika Therapeutics' latest filing, its Return on Capital Employed stood at 0.07% for Q3 2025, which was down 1600.0% from 0.05% recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Return on Capital Employed ranged from a high of 0.09% in Q3 2024 and a low of 0.11% during Q1 2021
  • Moreover, its 5-year median value for Return on Capital Employed was 0.02% (2021), whereas its average is 0.02%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first tumbled by -2100bps in 2021, then surged by 1200bps in 2024.
  • Over the past 5 years, Anika Therapeutics' Return on Capital Employed (Quarter) stood at 0.01% in 2021, then skyrocketed by 40bps to 0.01% in 2022, then plummeted by -73bps to 0.0% in 2023, then tumbled by -937bps to 0.03% in 2024, then crashed by -178bps to 0.07% in 2025.
  • Its Return on Capital Employed was 0.07% in Q3 2025, compared to 0.05% in Q2 2025 and 0.04% in Q1 2025.